Rheumatoid Arthritis News

The emergence of biosimilar TNF inhibitors in Poland led to reduced prices and expenditures, but little improvements in treatment availability, according to data published in Annals of the Rheumatic Diseases.

Following last year’s U.S. Supreme Court’s decision overturning federal abortion protections, rheumatologists must change their practice with regard managing patients’ reproductive health, said presenter at the 2023 AWIR annual conference.

Rheumatologists can help patients with lupus and other rheumatic diseases avoid potentially dangerous unintended pregnancies by regularly documenting their contraception use, according to a presenter at the 2023 AWIR annual conference.

When taken over 2 years for rheumatoid arthritis, low-dose glucocorticoids were associated with slight weight gain, but they did not significantly affect BP, according to research published in Annals of Internal Medicine.

AUSTIN, Texas — Providers should carefully consider the “lipid paradox” when monitoring cardiovascular risks in patients with rheumatic inflammatory diseases, noted a presenter at the 2023 Rheumatology Nurses Society annual conference.

The adalimumab biosimilar Hadlima achieved its pharmacokinetic similarity endpoints in a phase 4 interchangeability study, according to a press release from the manufacturer.

AUSTIN, Texas — Ongoing communication between rheumatology and pulmonology is essential to managing “unpredictable” interstitial lung disease, according to a presenter at the 2023 Rheumatology Nurses Society annual conference.

The FDA has granted final approval to Zydus Lifesciences to manufacture and market generic indomethacin 50 mg suppositories, according to a company press release.

Researchers said they developed a comprehensive score that can identify patients at high risk for inflammatory arthritis, as well as a “simple score” that can identify patients at low risk, both of which “may be useful in clinical care.”

Although major adverse cardiac events, malignancy and venous thromboembolism are more frequent in at-risk patients with rheumatoid arthritis, rates are similar between those receiving upadacitinib vs. adalimumab, according to data.